Source comparison
CJC-1295 No DAC 50s Protocol: Comparison Table
Before writing content, this table compares standard CJC-1295 protocols to the age-adjusted protocol required for 50+ populations. Dosing Range 200–500mcg per injection 100–200mcg per injection Somatotroph density declines 30–40% by age 50; receptor saturation
This comparison does not assign a generated winner or score.
- Before writing content, this table compares standard CJC-1295 protocols to the age-adjusted protocol required for 50+ populations.
- Dosing Range
- 200–500mcg per injection
- 100–200mcg per injection
- Somatotroph density declines 30–40% by age 50; receptor saturation occurs at lower doses
- Lower dosing ceiling prevents receptor oversaturation without sacrificing efficacy
- Injection Frequency
- 1–2x weekly
- 2–3x weekly
- Endogenous GH pulse amplitude flattens with age; more frequent low-dose pulses preserve pulsatility
- Maintains physiological rhythm without supraphysiological spikes
- IGF-1 Target Range
- 250–350 ng/mL
- 180–250 ng/mL
- IGF-1 >250 ng/mL increases neoplastic and cardiovascular risk in aging populations
- Conservative range balances anabolic benefit with long-term safety
- Monitoring Interval
- Every 8–12 weeks
- Every 4–6 weeks (first 3 months)
- Age-related insulin resistance and lipid dysregulation require tighter tracking
- Catches glucose or IGF-1 elevation before complications occur
- Contraindications
- Active malignancy, uncontrolled diabetes
- Same + proliferative retinopathy, HbA1c >7.5%
- GH amplifies existing pathology. Stricter screening required in older populations
- Age-specific medical history screening is non-negotiable